Please click on the link to see a list of melanoma journal articles that came across the MRV desk recently.
Archive | Scientific Publications
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
Given that objective responses in 30% to 50% of patients suffering from metastatic melanoma is mediated by adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TIL), as per multiple, small phase 2 trials, so, researchers assessed long-term clinical outcomes, intent-to-treat analysis, predictors of response as well as toxicity profile in a large patient cohort.
Posted in Melanoma News, Publications, Scientific Publications
Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo : A secondary analysis of a randomized clinical trial
In the present study, the researchers sought to explore the connection between immune-related adverse events and recurrence-free survival (RFS) in the double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of individuals with high-risk stage III melanoma.
Posted in Melanoma News, Publications, Scientific Publications
The prognostic impact of the extent of ulceration in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)
This study was undertaken to determine if the extent of ulceration (EU) predicts relapse free survival (RFS) and overall survival (OS) in primary cutaneous melanoma (PCM).
Posted in Melanoma News, Publications, Scientific Publications
